Adjuvant chemotherapy improves survival in patients with American Joint Committee on Cancer stage II colon cancer

Cancer

Volumn 117, Issue 24, 2011, Pages 5493-5499

  McKenzie, Shaun ^a   Nelson, Rebecca ^b   Mailey, Brian ^b   Lee, Wendy ^b   Chung, Vincent ^b   Shibata, Stephen ^b   Garcia Aguilar, Julio ^b   Kim, Joseph ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

adjuvant; American Joint Committee on Cancer stage II; California Cancer Registry; chemotherapy; colon cancer

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; ADULT; AGE; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; COLON CANCER; COLON RESECTION; CONTROLLED STUDY; FEMALE; HEMICOLECTOMY; HUMAN; INTERMETHOD COMPARISON; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; SEX DIFFERENCE; TOTAL COLON RESECTION; TREATMENT OUTCOME; TUMOR DIFFERENTIATION; TUMOR LOCALIZATION; TUMOR VOLUME;

CALIFORNIA; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; COLONIC NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 82955233100     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26245     Document Type: Article

References (28)

1. Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics, 2010. CA Cancer J Clin. 2010; 60: 277-300.
2. De Dosso S, Sessa C, Saletti P,. Adjuvant therapy for colon cancer: present and perspectives. Cancer Treat Rev. 2009; 35: 160-166.
3. O'Connell JB, Maggard MA, Ko CY,. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst. 2004; 96: 1420-1425. (Pubitemid 39429665)
4. Figueredo A, Charette ML, Maroun J, Brouwers MC, Zuraw L,. Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group. J Clin Oncol. 2004; 22: 3395-3407. (Pubitemid 41103699)
5. Mamounas E, Wieand S, Wolmark N, et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from 4 National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol. 1999; 17: 1349-1355. (Pubitemid 29220839)
6. Moertel CG, Fleming TR, Macdonald JS, et al. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. J Clin Oncol. 1995; 13: 2936-2943.
7. Morris M, Platell C, McCaul K, et al. Survival rates for stage II colon cancer patients treated with or without chemotherapy in a population-based setting. Int J Colorectal Dis. 2007; 22: 887-895. (Pubitemid 46952037)
8. Quasar Collaborative Group, Gray R, Barnwell J, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007; 370: 2020-2029.
9. Schippinger W, Samonigg H, Schaberl-Moser R, et al. A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer. Br J Cancer. 2007; 97: 1021-1027. (Pubitemid 47587021)
10. Schrag D, Rifas-Shiman S, Saltz L, Bach PB, Begg CB,. Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. J Clin Oncol. 2002; 20: 3999-4005.
11. Wilkinson NW, Yothers G, Lopa S, Costantino JP, Petrelli NJ, Wolmark N,. Long-term survival results of surgery alone versus surgery plus 5-fluorouracil and leucovorin for stage II and stage III colon cancer: pooled analysis of NSABP C-01 through C-05. A baseline from which to compare modern adjuvant trials. Ann Surg Oncol. 2010; 17: 959-966.
12. Wolmark N, Colangelo L, Wieand S,. National Surgical Adjuvant Breast and Bowel Project trials in colon cancer. Semin Oncol. 2001; 28 (1 suppl 1): 9-13. (Pubitemid 32173098)
13. Gervaz P, Bouzourene H, Cerottini JP, et al. Dukes B colorectal cancer: distinct genetic categories and clinical outcome based on proximal or distal tumor location. Dis Colon Rectum. 2001; 44: 364-372; discussion 372-363.
14. Quah HM, Chou JF, Gonen M, et al. Identification of patients with high-risk stage II colon cancer for adjuvant therapy. Dis Colon Rectum. 2008; 51: 503-507.
15. Chang GJ, Rodriguez-Bigas MA, Skibber JM, Moyer VA,. Lymph node evaluation and survival after curative resection of colon cancer: systematic review. J Natl Cancer Inst. 2007; 99: 433-441. (Pubitemid 47073566)
16. Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol. 2004; 22: 1797-1806. (Pubitemid 41095169)
17. Chen HS, Sheen-Chen SM,. Obstruction and perforation in colorectal adenocarcinoma: an analysis of prognosis and current trends. Surgery. 2000; 127: 370-376.
18. Petersen VC, Baxter KJ, Love SB, Shepherd NA,. Identification of objective pathological prognostic determinants and models of prognosis in Dukes' B colon cancer. Gut. 2002; 51: 65-69. (Pubitemid 34717746)
19. National Institutes of Health consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA. 1990; 264: 1444-1450.
20. O'Connell MJ, Campbell ME, Goldberg RM, et al. Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set. J Clin Oncol. 2008; 26: 2336-2341.
21. de Gramont A, Hubbard J, Shi Q, et al. Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set. J Clin Oncol. 2010; 28: 460-465.
22. Kuebler JP, Wieand HS, O'Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol. 2007; 25: 2198-2204. (Pubitemid 46954643)
23. Lembersky BC, Wieand HS, Petrelli NJ, et al. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol. 2006; 24: 2059-2064. (Pubitemid 46622115)
24. Wolmark N, Rockette H, Fisher B, et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol. 1993; 11: 1879-1887. (Pubitemid 23304611)
25. Taal BG, Van Tinteren H, Zoetmulder FA,. Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III. Br J Cancer. 2001; 85: 1437-1443. (Pubitemid 34001570)
26. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. J Clin Oncol. 1999; 17: 1356-1363.
27. Benson AB, 3rd, Schrag D, Somerfield MR, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004; 22: 3408-3419. (Pubitemid 41103700)
28. Engstrom PF, Arnoletti JP, Benson AB, 3rd, et al. NCCN Clinical Practice Guidelines in Oncology: colon cancer. J Natl Compr Canc Netw. 2009; 7: 778-831.